Related Experiment Video
Updated: Jan 14, 2026
A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19
Published on: July 5, 2022
Comparing computable type 2 diabetes phenotype definitions in identifying populations of interest for clinical
Priyanka D Sood1, Star Liu2, Rita R Kalyani3
1Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Objective:
Significant variations exist in computable phenotype definitions to identify patients with type 2 diabetes (T2D) using electronic health records (EHRs). These variations cause challenges in identifying T2D populations for clinical research. To address these challenges, this study compares the variations in common phenotypes in identifying patients with T2D using EHRs.
Methods:
A retrospective data analysis was performed using clinical data extracted from EHRs of 207 813 adult patients captured 2017-2019. Multiple T2D phenotypes were used: (1) Surveillance, Prevention and Management of Diabetes Mellitus, (2) Centers for Medicare and Medicaid Services Chronic Conditions Data Warehouse (CCW), (3) eMERGE Northwestern Group, (4) Durham Diabetes Coalition (DDC) and (5) a definition developed by a panel of experts at Johns Hopkins.
Results:
Each phenotype definition identified a different T2D population with a unique composition of demographics and clinical features. Although the identified patients overlapped across phenotypes, only 22.7% (47 326) of the population was commonly identified across all definitions. Of the phenotypes, DDC identified the greatest number of patients with T2D (139 832, 67.3%), while CCW had the highest mean age (65.3 years), the highest percentage of black patients (35%) and the highest mean Charlson comorbidity score of 2.96. DDC identified patients with T2D with the lowest means of inpatient (0.64) and emergency room (1.06) visits.
Conclusion:
Our study highlights the complexity of computable T2D phenotypes in translating commonly agreed T2D clinical definitions when applied against retrospective EHR data. Our findings provide an understanding of using appropriate phenotypes to identify, enrol and analyse T2D populations of interest using EHR data.
More Related Videos
08:13Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT
Published on: January 7, 2018
09:52Generation of High Quality Chromatin Immunoprecipitation DNA Template for High-throughput Sequencing ChIP-seq
Published on: April 19, 2013
Related Concept Videos
01:22Diabetes Mellitus: Type 2 and Gestational
01:15Diabetes: Symptoms, Diagnosis, and Complications
01:20Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
01:22Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
01:36Carbohydrate Metabolism
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...